Literature DB >> 1390176

Verapamil-induced secondary erythermalgia.

J P Drenth1, J J Michiels, T Van Joost, V D Vuzevski.   

Abstract

A 59-year-old man developed red, swollen and warm feet accompanied by intermittent burning pain during treatment for cardiac failure and arrhythmias with several drugs including verapamil. The condition gradually worsened until there was persistent disabling burning pain and severe erythema and swelling of the feet. Aspirin and other analgesics were ineffective in relieving the discomfort. Histopathology of punch biopsies showed a mild perivascular mononuclear infiltrate and moderate perivascular oedema. Within 2 weeks of stopping verapamil the burning pain, erythema, and swelling of the feet had resolved. The clinical features and subsequent course are consistent with a diagnosis of erythermalgia secondary to verapamil.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1390176     DOI: 10.1111/j.1365-2133.1992.tb00132.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

Review 1.  A comparative review of the adverse effects of calcium antagonists.

Authors:  H T Dougall; J McLay
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 2.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

3.  The primary erythermalgia-susceptibility gene is located on chromosome 2q31-32.

Authors:  J P Drenth; W H Finley; G J Breedveld; L Testers; J J Michiels; G Guillet; A Taieb; R L Kirby; P Heutink
Journal:  Am J Hum Genet       Date:  2001-03-20       Impact factor: 11.025

4.  Acute secondary erythermalgia and hypertension in children. Erythermalgia Multidisciplinary Study Group.

Authors:  J P Drenth; J J Michiels; S Ozsoylu
Journal:  Eur J Pediatr       Date:  1995-11       Impact factor: 3.183

Review 5.  Current pain management strategies for patients with erythromelalgia: a critical review.

Authors:  See Wan Tham; Marian Giles
Journal:  J Pain Res       Date:  2018-08-30       Impact factor: 3.133

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.